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Cannabinoids in Duchenne’s 
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Fabio Arturo Iannotti
Abstract
The scientific community uses the term endocannabinoid system (ECS) to refer 
to a large group of molecules that in our body control the production and function 
of the two major cannabinoid lipid mediators, namely, anandamide (AEA) and 
2-arachidonoylglycerol (2-AG). Following their discovery, an impressive number 
of studies have shown that both AEA and 2-AG play a key role in a large plethora of 
functions in living organisms. Consequently, functional impairment or dysregula-
tion of AEA and 2-AG activity leads to a variety of disorders affecting the nervous 
system as well as peripheral organs and tissues. For this reason, cannabinoids and/
or cannabinoid synthetic drugs currently represent an important area of research 
for their potential therapeutic use to treat many human diseases having or not 
a genetic component. Despite these evidences, the role of the endocannabinoid 
system and hence potential changes in its activity in inherited muscular dystrophies 
remains largely unknown. Only recently, the role of endocannabinoid CB1 receptors 
was identified in Duchenne’s muscular dystrophy (DMD). In this chapter, I sum-
marize the chemical properties and functional role of the endocannabinoids as well 
as plant-derived cannabinoids during skeletal muscle formation and repair under 
physiological conditions as well as DMD.
Keywords: endocannabinoid system (ECS), endocannabinoids (ECs), cannabidiol 
(CBD), cannabidivarin (CBDV), cannabinoid receptor of type 1 (CB1), Duchenne’s 
muscular dystrophy (DMD), transient receptor potential cation channels (TRP 
channels), anandamide (AEA), 2-arachidonoylglycerol (2-AG)
1. Introduction
1.1 Description of the endocannabinoid system (ECS)
The term endocannabinoid system (ECS) was originally coined in the 1990s 
after the discovery of brain receptors, responsive to ∆9-tetrahydrocannabinol-THC 
(the primary psychoactive substance of Cannabis sativa) and the class of their 
endogenous ligands identified immediately thereafter [1]. Since these discoveries, 
the number of molecules functionally associated with the activity of the endocan-
nabinoid system has grown exponentially.
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Nowadays, the ECS is considered to be a very complex network of connected 
signaling molecules, and key components of this system include (a) the two most 
potent endogenous agonists of cannabinoid receptors, anandamide (AEA) and 
2-arachidonoyl-glycerol (2-AG), also named endocannabinoids;  
(b) endocannabinoid-related molecules including N-oleoylethanolamine (OEA) 
and N-palmitoylethanolamide (PEA); (c) the enzymes regulating the endocannabi-
noid biosynthesis (NAPE-PLD, ABDH4, GDE1, PTPN22 for AEA, and DAGLα and 
DAGLβ for 2-AG) and degradation (FAAH for AEA and MAGL, ABDH6, ABDH12, 
and FAAH for 2-AG); (d) the two endocannabinoids responsive to G-protein-
coupled receptors known as cannabinoid receptor of type 1 (CB1) and type 2 (CB2); 
and (e) the cation permeant transient receptor potential vanilloid type-1 (TRPV1) 
[2–4]. Recently, AEA and 2-AG were also shown to have affinity for non-cannabi-
noid receptors including GABA-A, PPARγ, adenosine A3, and GPR55 [5]. In this 
complex scenario, also other endogenous AEA and 2-AG analogues, including other 
N-acyl-ethanolamines (NAEs), monoacylglycerols, N-acyl amino acids, and N-acyl-
dopamines/taurines/serotonins, were suggested to share, to some extent, either 
anabolic or catabolic pathways, or both, with endocannabinoids (Figure 1) [6].
As also mentioned previously, the endocannabinoid system (ECS) is critically 
involved in regulating a variety of metabolic and cognitive processes. An overactive 
endocannabinoid/CB1R system has been associated with the development of obe-
sity, insulin resistance, and dyslipidemia [7–10] as well as during the progression of 
neurological disorders such as Alzheimer’s disease, multiple sclerosis, amyotrophic 
Figure 1. 
Synthesis, inactivation, and mechanism of action of the two endocannabinoids anandamide and 2-AG. Thick 
black arrows indicate the biochemical reactions that starting from the precursor membranes lead to the 
synthesis of the two endocannabinoids anandamide and 2AG. ABDH4, α β-hydrolase 4; ABDH6, α 
β-hydrolase 6; ABDH12, α β-hydrolase 12; CB1 and CB2, cannabinoid receptor of types 1 and 2; COX2, 
cyclooxygenase 2; DAG, diacylglycerol; EMT, endocannabinoid membrane transporter; FAAH, fatty acid 
amide hydrolase; GDE1, glycerophosphodiester phosphodiesterase 1; MAGL, monoacylglycerol lipase; 
NAPE-PLD, N-acyl-phosphatidylethanolamine-selective phosphodiesterase; NATs, N-acyltransferases; PA, 
phosphatidic acid; PLCbeta, phospholipase Cbeta; PLD, phospholipase D; 15-LOX, 15-lipoxygenase; 
PTPN22, protein tyrosine phosphatase, non-receptor type 22; PGF2α, prostaglandin F2alpha; 15 HAEA, 
15(S)-HETE ethanolamide; PGE2, prostaglandin E2; TRPV1, transient receptor potential, vanilloid 
subtype 1 receptor (this figure was copied directly from Arturo, Iannotti Fabio, and Fabiana, Piscitelli 
(Nov. 2018) Endocannabinoidome. In: eLS. John Wiley & Sons Ltd, Chichester). http://www.els.net [doi: 
10.1002/9780470015902.a0028301].
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lateral sclerosis, Parkinson’s disease, and Huntington’s chorea [4, 11]. Nevertheless, 
the potential role of the ECS in skeletal muscle disorders remains largely unknown.
2.  What is known about the role of endocannabinoid systems in skeletal 
muscle
2.1  The role of the endocannabinoid system on glucose metabolism and insulin 
sensitivity in skeletal muscles
The first evidence demonstrating that CB1 receptors are functionally expressed 
in skeletal muscle tissues came out in 2005, when Liu and colleagues reported 
the effects of SR141716 (commonly known as rimonabant), one of the most used 
selective CB1 antagonists/inverse agonists [12], on energy expenditure and glucose 
uptake in isolated soleus muscle of obese Lep(ob)/Lep(ob) mice. In particular, the 
authors found that 5 days after daily treatment, SR141716 resulted in a significant 
reduction of daily food intake and body weight. While after 7 days, SR141716 had 
also positive effects on basal oxygen consumption and glucose uptake [13].
Few years later, Cavuoto and colleagues in two parallel studies demonstrated 
first that not only CB1 but also CB2, TRPV1, and FAAH are expressed in human 
and rodent skeletal muscle. Then, in human primary myotubes isolated from lean 
and obese donors, they found that the exposure to AEA or AM251 (another largely 
used selective CB1 antagonist), separately or in combination for 24 hours, induces 
significant changes in transcript levels of key genes regulating the metabolism such 
as AMP-activated protein kinase (AMPK) alpha 1 (alpha1) and alpha 2 (alpha2), 
pyruvate dehydrogenase kinase 4 (PDK4), and peroxisome proliferator-activated 
receptor-gamma coactivator-1alpha (PGC-1alpha) [14, 15].
Thus, these pioneering studies have paved the way for other studies through 
which the role of the ECS in regulating energy balance at the skeletal muscle 
level was further strengthened. In this regard, Esposito and colleagues showed 
that in differentiated L6 myotubes, the pharmacological blockade by SR141716 
or genetic silencing of CB1 small interfering RNA sequences increased 2-deoxy-
glucose uptake (2-DG) in a time- and dose-dependent manner. The authors 
also demonstrated that, the activity of phosphatidylinositol-3-kinase (PI3K) 
that in turn has stimulatory effects phosphoinositide-dependent kinase-1, Akt/
protein kinase B, and protein kinase Cζ, resulted increased by SR141716 [16]. 
Accordingly, Eckardt et al. found that in human skeletal muscle cells 24 hours 
of incubation with adipocyte-conditioned medium (CM) or anandamide (AEA) 
impaired insulin-stimulated Akt(Ser473) phosphorylation. By contrast, pretreat-
ment with rimonabant or AM251 reduced the effect of CM by about one-half, 
while the effect of AEA was fully prevented. The reduction of insulin-stimulated 
glucose uptake by CM was completely prevented by rimonabant. In addition, AEA 
was found to transiently activate ERK1/ERK2 and p38 mitogen-activated protein 
kinase and impaired insulin-stimulated Akt (Ser473) phosphorylation, but had no 
effect on Akt (Thr308) and glycogen synthase kinase 3 alpha/beta phosphoryla-
tion. Surprisingly, after 24 hours of treatment, an enhanced IRS-1 (Ser307) phos-
phorylation induced by AEA was observed in human skeletal muscle cells [17]. 
Furthermore, activation or inhibition of CB1 receptor activity exerts a differential 
effect with regard to MAP kinase- and PKB-directed signaling [18]. In conclusion, 
all these studies provide robust evidence that the endocannabinoid “tone” (hence 
CB1 signaling) is dysregulated during the obesity where its overactivity generates 
detrimental consequences on insulin sensitivity and consequently glucose catabo-
lism in skeletal muscle cells.
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It is worth noticing, however, that there are some discrepancies in scientific 
literature on whether the stimulation or inhibition of CB1 receptors has positive or 
negative effects on glucose metabolism in skeletal muscles. These differences are 
likely due to the dose/concentration and incubation time of agonists and antago-
nists of CB1 or more simply to the experimental model used. For a more extensive 
overview on the results aforementioned, Heyman et al. have recently published an 
extensive literature review [19].
2.2 Changes in the ECS activity in response to physical exercise
In addition to the diet, the physical exercise also contributes to induce changes 
in ECS activity. In this regard, Sparling et al. were the first in 2003 to find a robust 
increase of AEA in plasma of young male volunteers subjected to a physical exer-
cise of moderate intensity. This trend of increase, but much less prominent, was 
observed also for 2-AG [20]. Other studies have further demonstrated the close 
relationship between the intensity and type of physical exercise and ECS activity. 
In particular, while an exercise of moderate intensity was confirmed to increase the 
plasma levels of AEA in human volunteers, surprisingly no changes in plasma ECs 
were observed following a very-high- and very-low-intensity exercise [21–23]. Of 
note, the increased ECS activity induced by exercise was positively correlated with 
the beneficial antidepressant effects of exercise at central as well as peripheral levels 
including sense of well-being, anxiety reduction, postexercise calm, and reduced 
pain sensation [20, 23–26]. Interestingly, Hill et al. found that augmentation of 
exercise-induced increase of endocannabinoid tone suppresses stress-associated 
behaviors and promotes hippocampal cell proliferation, in a manner dependent 
on stimulation of CB1 stimulation [27, 28]. In addition, Heyman et al. provided 
evidence in humans that following acute exercise AEA and BDNF, a key neuro-
trophic factor regulating the brain development and cognitive functions [19], were 
positively correlated at the end of exercise and after the 15-min recovery.
As yet, the genetic deletion of CB receptors from the brain on VTA GABAergic 
neurons decreased wheel-running performance in mice [29]. However, quite 
surprisingly, when Gamelin et al. evaluated changes in the levels of AEA and 2-AG 
as well as of congener molecules in high-fat (HFD) diet subjected to 12 weeks of 
exercise training, they found that the high-fat diet paired with exercise training 
had no effect on AEA, 2-AG, and AEA congener levels nor in the hypothalamus or 
hippocampus. However, CB1 expression levels were significantly increased in the 
hippocampus in response to HFD, exercise, and the combination of both, strength-
ening evidence for EC signaling involvement in neuronal plasticity following diet 
and/or exercise [30]. A more recent study shows differences in the circulating levels 
of 2-AG and AEA between male and female mice or between lines of mice bred for 
high levels of voluntary exercise, when compared to their nonselected control lines 
[31]. An increased ECS activity was also recently found in skeletal muscles of mice 
subjected to muscle atrophy induced by mechanical unloading, most likely due to 
the disuse-induced muscle inflammation or the altered glycolytic flux [32].
2.3 Changes in the ECS during the skeletal muscle formation
In spite of the important role played by the ECS in regulating the insulin sen-
sitivity and oxidation pathways in skeletal muscle cells, its potential involvement 
during skeletal muscle formation and regeneration is little known. In 2014, our 
research group has demonstrated for the first time that the 2-AG levels significantly 
declined after 3 days of murine C2C12 myoblasts exposure to differentiation media 
and remained reduced up to at least day 7 of the differentiation process. In contrast, 
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AEA was not significantly changed during the myotube formation. According to 
these results, we have also demonstrated that during myotube formation the expres-
sion profile of the entire class of genes involved in AEA synthesis and degradation 
was not significantly changed, whereas the expression of key genes regulating 
the 2-AG metabolism including Daglα and Magl was significantly decreased and 
increased, respectively. Of note, potential changes in the endogenous levels of AEA 
and 2-AG were also explored during the skeletal muscle formation in vivo. In this 
case, we found that the levels of AEA were reduced in murine quadriceps muscle 
between the embryonic (E18) and early postnatal (P4) conditions, to then rebound 
at postnatal day 14 (P14). On the other hand, 2-AG levels remained constant 
between the embryonic and early postnatal phases but then decreased by about 
50% at P14. In summary, there is evidence that during myogenesis, occurring both 
in vitro or in vivo, the endogenous levels of 2-AG decline with myotube formation 
and muscle growth, respectively. By contrast, the levels of AEA did not during 
the myotube formation in vitro but undergo oscillatory variations during muscle 
formation in vivo [33].
Furthermore, by the use of both pharmacological tools and techniques of gene 
silencing, we demonstrated that in murine and human myoblasts as well as human 
primary satellite cells, the stimulation of CB1 receptors with either exogenous or 
endogenously cannabinoids promotes myoblasts proliferation and inversely inhibits 
their differentiation in mature myotubes [33]. As yet, the stimulation of CB1 inhib-
its the activity of Kv7 (or KCNQ ) channels, a subclass of voltage-gated K
+ channels 
composed of five members (Kv7.1–Kv7.5) that once activated promote myogenesis 
[33–35].
It is worth noting that both proliferation and differentiation of muscle precursor 
cells are both processes that are found altered in Duchenne’s muscular dystrophy, 
thus representing one of the most severe causes underlying an inefficient muscle 
tissue regeneration, thus contributing to disease etiology and progression [36–38].
2.4 The role of the endocannabinoid system in Duchenne’s muscular dystrophy
Among the hereditary myopathies, Duchenne’s muscle dystrophy (DMD) 
represents the most frequent one, affecting predominantly young boys with a 
frequency of approximately 1:3500. Mutations in the X-linked gene encoding for 
the structural protein dystrophin, which plays a key structural role by physically 
linking the cytoskeleton to the surrounding extracellular matrix through the cell 
membrane, are the cause of the disease. The most frequent mutation are large 
intragenic deletions (65% of the cases), intragenic duplications (6–10% of the 
cases), or point mutations associated to other sequence variations (30–35% of 
the cases). Dysfunctional dystrophin leads to progressive and irreversible loss of 
muscle function [39–42].
As briefly mentioned earlier, it has been recently demonstrated that the lack 
of functional dystrophin is also the primary cause of an asymmetric cell divi-
sion, altered morphogenesis, and inefficient differentiation of satellite cells, the 
muscle stem cells normally deputed to regenerate injured muscle fibers [36, 38]. 
Surprisingly, the number of satellite cells was found significantly increased in both 
human and murine skeletal muscles affected by DMD. Thus, while at the early stage 
of DMD, satellite cell-mediated muscle regeneration is able to attenuate degenera-
tion; at later stages of disease progression, this process is inefficient [37, 43].
Therefore, in the light of these findings as well as the prominent role played by 
ECS during skeletal muscle cell and proliferation earlier described, my research 
group has explored whether the cannabinoids might represent a promising alterna-
tive approach to treat skeletal muscle disorders including DMD.
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Toward this goal, we have recently characterized the expression profile of the 
ECS in whole muscles and isolated myoblasts of both mice and patients affected 
by DMD. No statistically significant differences were found in 2-AG levels between 
healthy and DMD donors, while higher levels of 2-AG were found in the muscles of 
3-weeks-old mdx mice. However, 2-AG levels in both mdx mouse quadriceps and 
gastrocnemius, and in control gastrocnemius, first decreased (from 3 to 5 weeks of 
age) and then increased (from 5 to 8 weeks of age). Interestingly, 2-AG levels in the 
gastrocnemius were higher in mdx mice at 8 weeks and then 3 and 5 weeks.
Furthermore, in agreement with previous studies [36, 37, 43], we found that 
the total number of satellite cells isolated from skeletal muscles of mdx mice was 
significantly higher than in control mice. Intriguingly, by means of quantitative 
qPCR (qPCR) and RNA-Seq analysis, we demonstrated that the lack of dystrophin 
was accompanied by a significant increase in the transcript levels of CB1, occurring 
exclusively in satellite cells but not in other muscle resident cells including fibro-
adipogenic progenitor (FAP) or macrophage cells. Thus, we provided evidence that 
in both human and murine skeletal muscles affected by DMD occur significant 
changes in 2-AG levels. These changes are associated with an increased expression 
of CB1 gene and concomitant increase in the number of satellite cells [44].
In addition to these findings, we have also demonstrated that PAX7, the most 
known master gene regulating satellite cell activation and self-renewal [45, 46], 
underwent changes very similar to CB1 showing a bell-shaped profile with the high-
est degree of expression at DMD onset and declining then over time. Intriguingly, 
by the use of bioinformatics and biochemical analyses, it was demonstrated that 
PAX7 directly binds and upregulates the CB1 gene in dystrophic more than in 
healthy muscles. In summary, the incorrect PAX7-CB1 cross talk, causing an exces-
sive satellite cell proliferation and reduction of differentiation, was uncovered as a 
new target mechanism to treat DMD. Antagonism of CB1 receptors by rimonabant, 
opposite to their activation by ACEA, reduces human satellite cell proliferation and 
enhances the formation of myotubes from either satellite cells from healthy tissue or 
human myoblasts from DMD patients. Furthermore, in dystrophic mdx mice, the 
acute (2 weeks) or prolonged (12 weeks) treatment with rimonabant significantly 
prevented the loss of muscle coordination and strength compared to control (not 
treated) mice. Biochemical and histological analyses of mdx mice at the end of 
treatment revealed that the effect of rimonabant was associated with an increased 
number of healthy/regenerating fibers and decreased tissue levels of inflammatory 
markers including interleukin-6 receptor (IL-6R), tumor necrosis factor-α (TNFα), 
transforming growth factor β (TGF-β), and inducible nitric oxide synthase (iNOS) 
(Figure 2).
2.5 The use of plant-derived cannabinoids in Duchenne’s muscular dystrophy
In addition to endocannabinoids, our research group has also explored 
the use of plant-derived cannabinoids (or phytocannabinoids) to treat 
DMD. Phytocannabinoids encompass a group of numerous compounds present in 
Cannabis sativa. Due to its euphoric properties, Δ9-tetrahydrocannabinol (THC) 
is the best-known constituent of Cannabis [47]. However, many other phytocan-
nabinoids (more than 100) have been purified and chemically characterized [48]. 
Among them, cannabidiol (CBD) and its analog cannabivarin (CBDV), contrary 
to ∆9-THC, do not induce euphoric effects and showed their efficacy in a consider-
able number of preclinical as well as clinical studies [49–52]. Besides CBD and 
CBDV, Cannabis sativa may also contain up to 50% of ∆9-tetrahydrocannabivarin 
(THCV), the propyl side chain analog of THC ([53, 54]. THCV is also undergoing 
clinical evaluation for the treatment of metabolic disorders [55]. In differentiating 
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C2C12 myoblasts, we found that the CBD (1 μM) and CBDV (1 and 3 μM), but 
not THCV, significantly promoted the myotube formation. Intriguingly, this 
latter effect was more pronounced following acute (5, 15 min and 3 hours) rather 
than the prolonged (72 hours) exposure and associated with a transient elevation 
of [Ca2+]i in a manner dependent on TRPV1 channel activation. The efficacy of 
CBD and CBDV has been then demonstrated in vivo. In mdx mice of 5 weeks, the 
most used animal model of DMD [56, 57], we found that the locomotor activity 
measured by means of three different tests (rotarod, weight, and forelimb grip 
strength) was rescued completely when compared to control vehicle-treated mice. 
Of note, the effect of CBD and CBDV in mdx mice was not only found at 7 weeks 
(a time near the disease onset) but also at 34 weeks, when the muscle damage had 
further progressed. Interestingly, the beneficial effects of the phytocannabinoids 
were associated with a local or systemic anti-inflammatory effect and restora-
tion of autophagy, two pathophysiological features of DMD (Figure 2) [36, 58]. 
However, in our recent published study, we did not perform a detailed time-course 
experiments; therefore, we cannot draw any conclusion as to whether the anti-
inflammatory effects of the phytocannabinoids are the cause or the consequence 
of their pro-autophagic actions nor on whether at different stages of the disease; 
these compounds may affect myoblast differentiation. On the other hand, the find-
ing of their anti-inflammatory and pro-autophagic actions opens the possibility of 
testing CBD and CBDV as add-on therapeutics to other agents that are currently 
undergoing clinical trials in DMD, such as exon-skipping agents [59]. However, it 
is worth mentioning that mdx mice do not model appropriately all aspects of the 
human DMD disease. Therefore, while beyond the scope of the present investiga-
tion, future studies in more suitable models, such as the golden retriever dog model 
[56, 57], are needed in order to suggest the therapeutic use of CBD and CBDV 
in DMD. In primary human satellite cells, CBD and CBDV and also THCV were 
capable of enhancing differentiation. Most importantly similar were also obtained 
in differentiating myoblasts isolated from seven different donors (ranging from 
1 to 7 years old) diagnosed with DMD. Thus, these results potentially extended 
the therapeutic usefulness of these compounds at counteracting dystrophies. 
Interestingly, in satellite cells, the target through which these compounds produce 
their differentiating effect appears to be different from that mediating this effect 
in murine C2C12 myoblasts. In fact, TRPA1, rather than TRPV1, channels mediated 
an elevation of [Ca2+]i.
Figure 2. 
Graphical representation showing the effects of cannabinoids in mdx mice.
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of the Creative Commons Attribution License (http://creativecommons.org/licenses/
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provided the original work is properly cited. 
3. Conclusions
Inherited muscular dystrophies originating from mutations in one of the 
components forming the dystrophin glycoprotein complex show specific features 
but similar clinical characteristics. Albeit controversial, no overt clinical improve-
ment was observed in patients with DMD under current therapies. For this reason, 
the identification of therapies capable of alleviating the progression of the disease 
is imperative. There are emerging evidences that the pharmacological regulation 
of ECS activity as well as the use of certain phytocannabinoids may attenuate the 
progressive and irreversible loss of muscle function. In conclusion, there is hope 
that the use of cannabinoids in DMD could represent a keystone to open new fields 
of research in discovering novel mechanisms able to preserve muscle tissue activity 
by preserving its integrity or promoting its regeneration.
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